National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic

Tools

Palmateer, N.E. and Dickson, E. and Furrie, E. and Godber, I. and Goldberg, D.J. and Gousias, P. and Jarvis, L. and Mathie, L. and Mavin, S. and McMenamin, J. and McNeilly, T.N. and Murcia, P. and Murray, J. and Reid, G. and Robertson, C. and Templeton, K. and von Wissmann, B. and Wallace, L.A. and Waugh, C. and McAuley, A. (2021) National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic. Public Health, 198. pp. 102-105. ISSN 1476-5616 (https://doi.org/10.1016/j.puhe.2021.07.006)

[thumbnail of Palmateer-etal-PH-2021-National-population-prevalence-of-antibodies-to-SARS-CoV-2]
Preview
 Text. Filename: Palmateer_etal_PH_2021_National_population_prevalence_of_antibodies_to_SARS_CoV_2.pdf
Accepted Author Manuscript
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (705kB)| Preview

Abstract

Objectives: Studies that measure the prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ('seroprevalence') are essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic individuals. We aimed to measure seroprevalence in the Scottish population over the course of the COVID-19 pandemic – from before the first recorded case in Scotland through to the second pandemic wave. Study design: The study design of this study is serial cross sectional. Methods: We tested 41,477 residual samples retrieved from primary and antenatal care settings across Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (before rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in seroprevalence estimates and weekly SARS-CoV-2 notifications were compared. Results: Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the summer (range: 3%–5%) during a period of social restrictions, after which they increased concurrently with the second wave, reaching 9.6% (95% confidence interval [CI]: 8.4%–10.8%) in the week beginning 28th December in 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio [AOR]: 0.70, 95% CI: 0.61–0.79) and among individuals aged 20–39 years and 60 years and older (AOR: 0.74, 95% CI: 0.64–0.86; AOR: 0.80, 95% CI: 0.69–0.91, respectively) relative to those aged 0–19 years. Conclusions: After two waves of the COVID-19 pandemic, less than one in ten individuals in the Scottish population had antibodies to SARS-CoV-2. Seroprevalence may underestimate the true population exposure as a result of waning antibodies among individuals who were infected early in the first wave.

CORE (COnnecting REpositories)